BMB. C. Mamatha

B. C. Mamatha

*This is an algorithmically generated author record based on publicly available information.

B. C. Mamatha has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mechanistic Evaluation of Abutilon indicum Extract and Syringaldehyde in Ovalbumin-Induced Airway Inflammation Using Computational and Experimental Approaches

    by B. C. Mamatha, S. Vijaya Kumar, Pavithra Pradeep Prabhu, Akhil Nair, K. Mangala Shenoy, Suvarna Kini, Wilona Loren Lobo, Nitha Naveen Dsouza, Srikanth Jupudi, Ashwini Prabhu, et al.

    Abutilon indicum Linn. is a traditionally used medicinal herb in the treatment of inflammatory diseases. Syringaldehyde (SYD) is a major phytoconstituent of A. indicum. To compare the mast cell stabilizing and anti-asthmatic effects of hydroalcoholic extract of A. indicum (HAEAI) and SYD, and to explore the possible molecular mechanisms. Compound 48/80 (C48/80) induced mesenteric mast cell degranulation in rats was evaluated after 7 days of SYD (25 mg/kg and 50 mg/kg) and HAEAI (200 mg/kg and 400 mg/kg). Anti-asthmatic activity was assessed in ovalbumin (OVA)-induced allergic asthma in mice, with SYD and HAEAI administered during the challenge phase. Inflammatory cell counts in blood and bronchoalveolar lavage fluid (BALF) were quantified. BALF Th2 cytokines (IL-4 and IL-13) and serum OVA-specific IgE were measured by ELISA, and lung histopathology was performed. Network pharmacology, molecular docking, and molecular dynamics simulation were used for mechanistic evaluation. SYD and HAEAI showed a substantial effect by inhibiting C48/80-induced degranulation of mast cells ([Formula: see text] < 0.0001). In OVA-challenged mice, both treatments decreased inflammatory cell infiltration in BALF and blood, compared with the inducer control group, which showed elevated BALF cytokine levels of IL-4 (98.50 ± 6.56 pg/mL) and IL-13 (159.91 ± 9.56 pg/mL); treatment with HAEAI and SYD significantly reduced these inflammatory markers. HAEAI decreased IL-4 levels to 84.95 ± 3.73 pg/mL at the low dose and 67.20 ± 3.02 pg/mL at the high dose, while SYD reduced IL-4 levels to 66.91 ± 3.88 pg/mL and 55.90 ± 3.32 pg/mL at the low and high doses, respectively. Similarly, HAEAI reduced IL-13 levels to 143.50 ± 6.96 pg/mL at the low dose and 91.83 ± 9.06 pg/mL at the high dose, whereas SYD lowered IL-13 levels to 118.42 ± 4.86 pg/mL and 55.69 ± 3.74 pg/mL at the low and high doses, respectively. In addition, serum OVA-specific IgE levels were markedly reduced in the treatment groups compared with the inducer control group (557.84 ± 3.39 ng/mL). HAEAI reduced IgE levels to 378.44 ± 1.94 ng/mL at the low dose and 180.90 ± 1.30 ng/mL at the high dose. SYD also lowered serum OVA-specific IgE levels to 323.56 ± 1.93 ng/mL and 222.15 ± 1.55 ng/mL at the low and high doses, respectively. These findings indicate that both HAEAI and SYD exert significant anti-allergic effects by suppressing Th2 cytokines and reducing OVA-specific IgE production. and improved lung histopathology. In silico analysis showed a multi-target effect on allergic and inflammatory signaling. Following docking, a favorable ligand–protein interaction was observed during simulation. SYD and HAEAI have good mast cell stabilizing and anti-asthmatic effects, likely mediated through suppression of Th2-induced inflammation and multi-targeting allergic signaling pathways.

  • Riboflavin and Thymine from Abutilon indicum Linn. Mitigate Allergic Responses: An Integrated network pharmacology, In-silico analysis, MD Simulation, In vitro and Ex vivo Studies

    by B. C. Mamatha, Sharfuddin Mohd, Vancha Harish, Ashwini Prabhu, Durgesh Paresh Bidye, Sheshagiri R. Dixit, B. C. Revanasiddappa, Aravinda Pai, Shareef Shaik

    Abutilon indicum Linn., commonly known as Indian mallow, is known for its diverse pharmacological properties. This study investigates the anti-allergic and protective effects of hydro alcoholic extract of A. indicum (HAEAI) and two bioactive compounds, riboflavin and thymine, from A. indicum, using both in vitro and in vivo models. Cytotoxicity of these molecules was evaluated through the MTT assay on RBL-2H3 cells. Additionally, their anti-allergic effects were assessed using an ex vivo study, evaluating mast cell degranulation induced by Compound 48/80 in rat mesentery and the percentage protection of mast cells was quantified. Ionomycin was used to stimulate RBL-2H3 cells and mediator release. The degranulation levels of the compounds were assessed using the [ ]-hexosaminidase and histamine release assay. Additionally, the expression levels of cytokines, including TNF-[ ], IL-4, IL-6 and IL-13, were quantified using ELISA. The network consisting of composition, targets, and disease has been established. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. Molecular docking techniques were used to simulate the binding affinity of active compounds to target proteins, while molecular dynamics were applied to validate the results obtained from the molecular docking. Riboflavin, Thymine and extract were found to be non-toxic on RBL-2H3 cells. Results demonstrated inhibition of the allergic response induced by Ionomycin. Hence, these two compounds present in Abutilon indicum Linn., emerged as potential drug candidates and can be used in the management of allergic conditions.